Jagsonpal Q4 PAT up 31%, Revenue up 10%; ₹40 Cr Buyback, 200% Dividend
Jagsonpal Pharmaceuticals Ltd announced its audited financial results for Q4 and the full year ended March 31, 2026. For Q4 FY26, revenue increased by 10% YoY to ₹642 Mn, and Profit After Tax (PAT) grew significantly by 31% to ₹88 Mn. For the full fiscal year FY26, revenue rose by 7% to ₹2,872 Mn, and PAT increased by 19% to ₹446 Mn. The company maintained operational discipline with an FY26 Operating EBITDA of ₹609 Mn (21.2% margin). Jagsonpal also reported a robust cash balance of ₹1,907 Mn (₹191 Cr) as of March 31, 2026. The Board approved a buyback of up to 16 lakh equity shares (2.4% of total equity) at ₹250 per share, totaling ₹40 Cr, with promoters not participating. Additionally, a 200% dividend (including a 75% special dividend) was recommended, amounting to a total cash outlay of ~₹262 Mn.
Key Highlights
- Q4FY26 Revenue increased 10% YoY to ₹642 Mn; PAT surged 31% to ₹88 Mn.
- FY26 Revenue grew 7% to ₹2,872 Mn; PAT rose 19% to ₹446 Mn.
- Board approved ₹40 Cr buyback (16 lakh shares at ₹250/share) to enhance shareholder value.
- Recommended 200% dividend (including 75% special dividend) with ~₹262 Mn outlay.
- Strong cash balance of ₹1,907 Mn (₹191 Cr) as of March 31, 2026.